Biomedical Advanced Research and Development Authority (BARDA)

As the J.P. Morgan Healthcare Conference takes place this week, the President of Johnson & Johnson Innovation – JJDC, Inc. shares some of the scientific breakthroughs and collaborations his team is championing to help address the unmet needs and well-being of people around the world.

With its global Phase 3 clinical trial now fully enrolled with approximately 45,000 adult participants, we share the most up-to-date information about the single-dose investigational vaccine candidate.

In response to a new Ebola outbreak in Guinea, Johnson & Johnson is providing up to 200,000 doses of its Ebola vaccine regimen to the country for a World Health Organization supported clinical trial. Learn more about the initiative and other top facts about the vaccine regimen for the deadly virus.

Scientists at the facility, opening in the nation’s capital this year, will be focused on advancing breakthrough ideas for safeguarding people around the world from pandemics like COVID-19, infectious diseases and other health threats.

From work on an investigational vaccine candidate to a $50 million commitment in support of healthcare workers on the very front lines of the crisis around the world, learn how the company has taken action to help respond to the pandemic.

Chairman & CEO Alex Gorsky shares that the company could have the first batches of a COVID-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.

From a donation of a million masks to help protect vulnerable healthcare workers to committed research on a potential vaccine, the company has activated quickly in several key ways to help address the outbreak.